Robeauté is redefining the future of brain therapies with the first microrobotic platform of its kind, designed to navigate the human brain with unprecedented precision. The new generation of microrobots can diagnose, treat and monitor the brain from within, overcoming long-standing limitations in treating neurological conditions that affect more than one in three people worldwide.

By bridging the gap between therapeutic innovation and deep physical access to the brain, our technology aims to support safe, targeted and intelligent brain interventions, bringing outsized value to patients, clinicians, and health systems globally.

Since our founding in 2017, we’ve filed over 50 patents and successfully tested our technology in living animals. Human clinical trials are targeted for 2026/2027. Backed by €27M in Series A funding from Plural, Cherry Ventures, Kindred Ventures, and Brainlab, we are entering a new phase of growth.

As part of this expansion, we are look...